Effect of Different Specifications of Symbicort Turbuhaler on the Treatment of Patients with Bronchial Asthma
Department of Pneumology, The First People’s Hospital of Lanzhou, No. 1 Wujiayuan West Street, Qilihe District, Lanzhou, Gansu 730050, China
Y. P. Wu, Department of Pneumology, The First People’s Hospital of Lanzhou, No. 1 Wujiayuan West Street, Qilihe District, Lanzhou, Gansu 730050, China, E-mail: email@example.com
To investigate the efficacy of different sizes of symbicort turbuhaler in the treatment of bronchial asthma and its effect on eosinophils. 138 patients diagnosed with bronchial asthma treated in our hospital from January 2019 to January 2020 were selected and randomly divided into high dose (n=69) and low dose groups (n=69) and both groups were treated with different doses of Symbicortol on top of the conventional treatment regimen, in which the low-dose group was 80 μg/4.5 μg/inhalation: 1 inhalation/inhalation, twice a day, for 8 w. The high dose was 160 μg/4.5 μg/inhalation: 1 inhalation/inhalation, twice a day, for 8 w. The results showed that after treatment, arterial partial pressure of oxygen decreased and arterial partial pressure of carbon dioxide and blood oxygen saturation increased in both groups compared with those before treatment, with more obvious changes in the high dose group (p<0.01). After treatment, forced expiratory volume, forced expiratory volume/forced vital capacity and peak expiratory flow levels were significantly increased (p<0.05), while peak expiratory flow rate percentage levels were significantly decreased (p<0.05) and the indexes in the high dose group were changes more obviously (p<0.01). The levels of eotaxin-2, C-C Motif Chemokine Receptor 3 and Mucin-5ACCurated were significantly lower after treatment (p<0.05) and the above indexes were significantly lower in the high dose group (p<0.01). The total clinical efficiency of the high dose group was 92.75 %, which was significantly higher than that of the low dose group (79.71 %) and the difference was statistically significant. There was no significant difference in the incidence rate between the two groups (p>0.05). In the treatment of bronchial asthma, different sizes of symbicort turbuhaler are able to control the disease, promote rapid recovery and improve the respiratory status of patients with an ideal safety.